EC grants marketing authorization for BENLYSTA to treat SLE

GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorization for BENLYSTA® (belimumab) 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy.

"The European approval of BENLYSTA represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with this chronic disease," said Dr. Tony Hoos, Senior VP, European Medical Affairs, GSK.

"We and GSK are committed to making BENLYSTA available in countries worldwide," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We are particularly honored to be bringing this medicine forward in Europe, where a number of key academic research institutions were very important to its clinical development."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adolescents' genetic risks tied to psychotic symptoms